223 related articles for article (PubMed ID: 37525911)
1. SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review.
Xu R; Lian D; Xie Y; Chen Z; Wang Y; Mu L; Wang Y; Zhang B
Front Biosci (Landmark Ed); 2023 Jul; 28(7):134. PubMed ID: 37525911
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence.
Yabiku K
Front Endocrinol (Lausanne); 2021; 12():768850. PubMed ID: 34950104
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms, screening modalities and treatment options for individuals with non-alcoholic fatty liver disease and type 2 diabetes.
Hydes TJ; Summers N; Brown E; Alam U; Thomaides-Brears H; Wilding JPH; Cuthbertson DJ
Diabet Med; 2020 Nov; 37(11):1793-1806. PubMed ID: 32619031
[TBL] [Abstract][Full Text] [Related]
4. An Update on the Effect Of Sodium Glucose Cotransporter 2 Inhibitors on Non-Alcoholic Fatty Liver Disease: A Systematic Review of Clinical Trials.
Alfayez AI; Alfallaj JM; Mobark MA; Alalwan AA; Alfayez OM
Curr Diabetes Rev; 2024; 20(2):e250523217349. PubMed ID: 37231725
[TBL] [Abstract][Full Text] [Related]
5. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
[TBL] [Abstract][Full Text] [Related]
6. SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection.
Androutsakos T; Nasiri-Ansari N; Bakasis AD; Kyrou I; Efstathopoulos E; Randeva HS; Kassi E
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328527
[TBL] [Abstract][Full Text] [Related]
7. The Long-term Efficacy of Sodium Glucose Co-transporter 2 Inhibitor in Patients with Non-alcoholic Fatty Liver Disease.
Yamashima M; Miyaaki H; Miuma S; Shibata H; Sasaki R; Haraguchi M; Fukushima M; Nakao K
Intern Med; 2019; 58(14):1987-1992. PubMed ID: 31308341
[TBL] [Abstract][Full Text] [Related]
8. SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review.
Raj H; Durgia H; Palui R; Kamalanathan S; Selvarajan S; Kar SS; Sahoo J
World J Diabetes; 2019 Feb; 10(2):114-132. PubMed ID: 30788048
[TBL] [Abstract][Full Text] [Related]
9. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies.
Stefan N; Häring HU; Cusi K
Lancet Diabetes Endocrinol; 2019 Apr; 7(4):313-324. PubMed ID: 30174213
[TBL] [Abstract][Full Text] [Related]
10. SGLT2 Inhibition for Cardiovascular Diseases, Chronic Kidney Disease, and NAFLD.
Ala M
Endocrinology; 2021 Dec; 162(12):. PubMed ID: 34343274
[TBL] [Abstract][Full Text] [Related]
11. Mendelian randomisation reveals Sodium-glucose Cotransporter-1 inhibition's potential in reducing Non-Alcoholic Fatty Liver Disease risk.
Dobbie LJ; Cuthbertson DJ; Hydes TJ; Alam U; Zhao SS
Eur J Endocrinol; 2023 Jun; 188(6):K33-K37. PubMed ID: 37343141
[TBL] [Abstract][Full Text] [Related]
12. SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease.
Mirarchi L; Amodeo S; Citarrella R; Licata A; Soresi M; Giannitrapani L
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409028
[TBL] [Abstract][Full Text] [Related]
13. SGLT-2 Inhibitors: Are They a Promising Treatment Option in T2DM Patients with NAFLD?
Patoulias D
Acta Medica (Hradec Kralove); 2017; 60(4):167-170. PubMed ID: 29716685
[TBL] [Abstract][Full Text] [Related]
14. Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease.
Makri ES; Goulas A; Polyzos SA
Eur J Pharmacol; 2021 Sep; 907():174272. PubMed ID: 34147478
[TBL] [Abstract][Full Text] [Related]
15. A look to the future in non-alcoholic fatty liver disease: Are glucagon-like peptide-1 analogues or sodium-glucose co-transporter-2 inhibitors the answer?
Vincent RK; Williams DM; Evans M
Diabetes Obes Metab; 2020 Dec; 22(12):2227-2240. PubMed ID: 32945071
[TBL] [Abstract][Full Text] [Related]
16. The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials.
Bica IC; Stoica RA; Salmen T; Janež A; Volčanšek Š; Popovic D; Muzurovic E; Rizzo M; Stoian AP
Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374340
[TBL] [Abstract][Full Text] [Related]
17. GLP-1 RAs and SGLT-2 Inhibitors for Insulin Resistance in Nonalcoholic Fatty Liver Disease: Systematic Review and Network Meta-Analysis.
Yan H; Huang C; Shen X; Li J; Zhou S; Li W
Front Endocrinol (Lausanne); 2022; 13():923606. PubMed ID: 35909522
[TBL] [Abstract][Full Text] [Related]
18. Sodium-Glucose Co-Transporter 2 Inhibitors for Non-Alcoholic Fatty Liver Disease in Asian Patients With Type 2 Diabetes: A Meta-Analysis.
Wong C; Yaow CYL; Ng CH; Chin YH; Low YF; Lim AYL; Muthiah MD; Khoo CM
Front Endocrinol (Lausanne); 2020; 11():609135. PubMed ID: 33643221
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials.
Mantovani A; Byrne CD; Scorletti E; Mantzoros CS; Targher G
Diabetes Metab; 2020 Nov; 46(6):427-441. PubMed ID: 31923578
[TBL] [Abstract][Full Text] [Related]
20. Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review.
Miao L; Xu J; Targher G; Byrne CD; Zheng MH
Clin Mol Hepatol; 2022 Oct; 28(4):725-738. PubMed ID: 35286799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
